Skip to main
NEO

NeoGenomics (NEO) Stock Forecast & Price Target

NeoGenomics (NEO) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

NeoGenomics is well-positioned in the oncology diagnostic testing market due to its wide range of tests, strong network of laboratories, and experienced staff, which provides a competitive advantage in this growing industry. With steady MSD% revenue growth expected in its clinical services business, and a faster growing NGS segment driving revenue growth of 10%+ over the next 3 years, NeoGenomics is poised for further success. Additionally, potential market share gains, test menu expansion, and positive reimbursement changes could further drive growth and increase its market value in the future.

Bears say

NeoGenomics is facing challenges with its NGS business due to competition and reimbursement pressure, and the appointment of a new CFO may bring uncertainty. In addition, while the company reported a modest beat and raise in 1Q including 23% NGS growth, margins remain low and the company may struggle to maintain this level of growth in the long term. Furthermore, the company's current valuation, trading at <2x EV/revenue, does not fully reflect these potential risks and uncertainties.

NeoGenomics (NEO) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeoGenomics (NEO) Forecast

Analysts have given NeoGenomics (NEO) a Buy based on their latest research and market trends.

According to 7 analysts, NeoGenomics (NEO) has a Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeoGenomics (NEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.